Corneal grafts may be more successful by using nanoparticles to encapsulate the medication. The novel approach could also significantly improve patient compliance.

Each nanoparticle encapsulates a drug called dexamethasone sodium phosphate, one of the most commonly used corticosteroids for treatment of various ocular diseases such as ocular inflammation, noninfectious uveitis, macular edema, and corneal neovascularization. By using the nanoparticles to control the release of the medicine over time, patients would require only one injection right after the corneal transplantation surgery rather than treatment with frequent eye drops.

The research team’s studies have shown that when using this method, the medication maintains its efficacy for six months on a corneal graft rejection model. More importantly, the nanoparticle approach reversed signs of early rejection and maintained corneal grafts for six months without rejection. (Image credit losmostachos/AdobeStock)

For more information, visit here  .

Topics:
Medical Nanomaterials Nanotechnology Nanotechnology Pharmaceuticals

More From SAE Media Group

Medical Design Briefs
Tendon Healing: Nanoparticles for Precision Drug Delivery
Related Article Image
Medical Design Briefs
Tiny Swimming Robots Treat Deadly Pneumonia in Mice
Related Article Image
Medical Design Briefs
Implantable Device Shrinks Pancreatic Tumors
Related Article Image
Medical Design Briefs
Targeted Drug Delivery: Nanomedicine Paves the Way for Treatments
Related Article Image
    Magazine cover
    Medical Design Briefs Magazine

    This article first appeared in the June, 2023 issue of Medical Design Briefs Magazine (Vol. 13 No. 6).

    Read more articles from this issue here.

    Read more articles from the archives here.